| A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.N Engl J Med | PMID 38381664无 PMCID | 2024-Feb-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.J Clin Psychiatry | PMID 38416865无 PMCID | 2024-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Feasibility of online managing cancer and living meaningfully (CALM) in Chinese patients with metastatic breast cancer: a pilot randomized control trial.Sci Rep | PMID 38418478PMC10902284 | 2024-Feb-28 | 0.95 | This is a pilot randomized controlled trial evaluating a psychotherapy (CALM) for psychological symptoms. It does not meet the core criteria: no drug intervention is present, and the primary efficacy endpoint is not time-to-event (OS, PFS, DFS, etc.). While it is a randomized oncology study in humans, it is also a pilot/feasibility study, not a definitive Phase III/IIIb or Phase II/III trial as required. | 待处理 |
| Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.Neurology | PMID 38295339PMC10962918 | 2024-Feb-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.Sci Bull (Beijing) | PMID 38185589无 PMCID | 2024-Feb-26 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial.Lancet | PMID 38346442无 PMCID | 2024-Feb-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nat Commun | PMID 38395969PMC10891118 | 2024-Feb-23 | 0.95 | The record is a Phase III randomized trial of a human oncology condition with time-to-event endpoints (RFS, OS) and reports a primary result. However, the intervention (autologous dendritic cell therapy) is a cell-based immunotherapy/biologic, not a conventional 'drug' (small molecule, antibody, etc.) as defined by the adjudication rules. Therefore, it fails the 'drug_intervention' criterion and is excluded. | 待处理 |
| Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.Br J Ophthalmol | PMID 36849205无 PMCID | 2024-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.Clin Cancer Res | PMID 38060199PMC10870115 | 2024-Feb-16 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.Clin Cancer Res | PMID 38109213PMC10956403 | 2024-Feb-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.Vaccine | PMID 38267330无 PMCID | 2024-Feb-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cefepime-Taniborbactam in Complicated Urinary Tract Infection.N Engl J Med | PMID 38354140无 PMCID | 2024-Feb-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.J Infect Dis | PMID 37506264PMC10873177 | 2024-Feb-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur).BMC Cancer | PMID 38350888PMC10863118 | 2024-Feb-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.J Immunother Cancer | PMID 38346853PMC10862253 | 2024-Feb-12 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.Acta Derm Venereol | PMID 38348724PMC10875623 | 2024-Feb-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.J Clin Oncol | PMID 38096461无 PMCID | 2024-Feb-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Lancet | PMID 38310910PMC7618965 | 2024-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines.Eur Heart J Acute Cardiovasc Care | PMID 38001050PMC10853690 | 2024-Feb-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials.Sleep | PMID 37875349PMC10851846 | 2024-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.N Engl J Med | PMID 38324483无 PMCID | 2024-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial.J Am Heart Assoc | PMID 38240204PMC11056111 | 2024-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.JAMA Netw Open | PMID 38335000PMC10858401 | 2024-Feb-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.Lancet | PMID 38281499PMC10850983 | 2024-Feb-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.Oncologist | PMID 37589219PMC10836324 | 2024-Feb-02 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.Oncologist | PMID 37699115PMC10836305 | 2024-Feb-02 | 0.85 | The study meets the oncology, human, randomized, phase, and original result criteria, but is excluded because the intervention is a dietary supplement (melatonin), not a drug, and the primary endpoint is patient-reported fatigue, not a time-to-event efficacy endpoint. | 待处理 |
| Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).Int J Radiat Oncol Biol Phys | PMID 37802225无 PMCID | 2024-Feb-01 | 0.85 | The trial is a randomized Phase III oncology study in humans with a drug intervention (ADT) and an original result. However, the primary endpoint (biochemical progression) is not one of the specified time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) required for inclusion in this adjudication. Secondary endpoints include OS and clinical progression, but these were not primary/key secondary in the sense of driving the trial's efficacy conclusion per the abstract. | 待处理 |
| Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.J Clin Oncol | PMID 37963317无 PMCID | 2024-Feb-01 | 0.80 | The record is from a randomized Phase II/III oncology trial with a drug intervention and is an original report. However, it does not report any primary or key secondary time-to-event efficacy endpoint, such as OS, PFS, DFS, or any endpoint analyzed with Kaplan-Meier or reported as an HR. The reported outcomes are surgical pathology, safety, and histopathologic regression rates, which are not time-to-event endpoints for efficacy in the context of this adjudication. | 待处理 |
| DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.J Clin Oncol | PMID 37992266PMC10824387 | 2024-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.JAMA Oncol | PMID 38095881PMC10722390 | 2024-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.JAMA Dermatol | PMID 38117487PMC10733845 | 2024-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.JAMA Neurol | PMID 38227308PMC10792497 | 2024-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.N Engl J Med | PMID 38294972无 PMCID | 2024-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized clinical trial of home telemonitoring in patients with advanced heart and lung diseases.J Telemed Telecare | PMID 34851202无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.Eur Urol | PMID 37085425PMC10662935 | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial.Eur Urol Oncol | PMID 37543465无 PMCID | 2024-Feb | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.J Thorac Oncol | PMID 37748693无 PMCID | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Clinical and cost-effectiveness of PCF versus ACD in the treatment of cervical brachialgia (FORVAD trial).Br J Neurosurg | PMID 37807634无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.Ann Oncol | PMID 37872020无 PMCID | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.Mov Disord | PMID 37886872无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.Psychiatry Clin Neurosci | PMID 37933521PMC11488604 | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.Diabetes Obes Metab | PMID 37945546无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial.Lancet Infect Dis | PMID 37949090无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).Br J Cancer | PMID 37973958PMC10803798 | 2024-Feb | 0.95 | The trial is a randomized Phase III study in oncology with a drug intervention, but its primary efficacy endpoint (complete response during delayed phase) is a categorical, non-time-to-event outcome. There is no mention of OS, PFS, DFS, or any other time-to-event endpoint, nor any Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint. | 待处理 |
| Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.Int J Clin Pharm | PMID 37991664无 PMCID | 2024-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.Lancet Infect Dis | PMID 38006892无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.Value Health | PMID 38042333无 PMCID | 2024-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.Breast Cancer Res Treat | PMID 38060077PMC10840989 | 2024-Feb | 0.90 | The study is a Phase IIB randomized trial focused on preventing chemotherapy-induced peripheral neuropathy, a toxicity. The primary endpoint is a functional assessment score (FACT-NTX), which is not a survival, progression, recurrence, death, or related efficacy outcome. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. | 待处理 |
| The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson's Disease.Adv Ther | PMID 38070039PMC10838837 | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.Cancer Sci | PMID 38098261PMC10859619 | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |